MedPath
FDA Approval

Cyclobenzaprine Hydrochloride

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
March 15, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Cyclobenzaprine(5 mg in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

St Mary's Medical Park Pharmacy

St Mary's Medical Park Pharmacy

063050751

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cyclobenzaprine Hydrochloride

Product Details

NDC Product Code
60760-536
Application Number
ANDA078643
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
March 15, 2023
STARCH, CORNInactive
Code: O8232NY3SJClass: IACT
HYPROMELLOSE 2910 (6 MPA.S)Inactive
Code: 0WZ8WG20P6Class: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48Class: IACT
POLYETHYLENE GLYCOL 400Inactive
Code: B697894SGQClass: IACT
D&C YELLOW NO. 10Inactive
Code: 35SW5USQ3GClass: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JPClass: IACT
Code: 0VE05JYS2PClass: ACTIBQuantity: 5 mg in 1 1
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
FD&C YELLOW NO. 6Inactive
Code: H77VEI93A8Class: IACT
© Copyright 2025. All Rights Reserved by MedPath